CytoLogic

About:

CytoLogic develops technology for treating cancerous tumors by enhancing the natural immune response to malignant cells.

Website: http://www.cytologic.com

Description:

CytoLogic, Inc., a medical device company, focuses on developing and commercializing a technology for treating cancerous tumors. The company’s UNLEASH therapy, which engages selective filtration of blood plasma on a dialysis-type platform, enhances a cancer patient’s natural immune response to malignant cells. Its UNLEASH technology depletes certain inhibitors of the body’s immune function enabling the patient’s immune system to fight malignant tumors. CytoLogic was founded in 1998 and is based in Boulder, Colorado.

Total Funding Amount:

$979000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boulder, Colorado, United States

Founded Date:

1998-01-01

Contact Email:

info(AT)cytologic.com

Founders:

Paul M. Thompson

Number of Employees:

1-10

Last Funding Date:

2012-06-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai